Anti-EWS-FLI1 Antibody, clone 1.1

Linear peptide corresponding to 91 amino acids from the C-terminal region of human EWS-FLI1.

Quality Control Testing

Evaluated by Western Blotting in SK-ES-1 cell lysate.

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected EWS-FLI1 in SK-ES-1 cell lysate but not in Colo357 cell lysate.

Tested Applications

Surface Plasmon Resonance: A representative lot of this antibody detected EWS-FLI1 in Surface Plasmon Resonance application (Selvanathan, S.P., et al. (2025). Antibodies (Basel). 14(4):97. (PMID:41283512)).

Dot Blot: A representative lot of this antibody detected EWS-FLI1 in Dot Blot application (Selvanathan, S.P., et al. (2025). Antibodies (Basel). 14(4):97. (PMID:41283512)).


Western Blotting Analysis: A representative lot detected EWS-FLI1 in Western Blotting application (Selvanathan, S.P., et al. (2025). Antibodies (Basel). 14(4):97. (PMID:41283512)).

Immunocytochemistry Analysis: A representative lot detected EWS-FLI1 in Immunocytochemistry application (Selvanathan, S.P., et al. (2025). Antibodies (Basel). 14(4):97. (PMID:41283512)).

Imunoprecipitation Analysis: A representative lot detected EWS-FLI1 in Immunoprecipitation application (Selvanathan, S.P., et al. (2025). Antibodies (Basel). 14(4):97. (PMID:41283512)).

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Clone 1.2 is a mouse monoclonal antibody that detects fusion protein EWS-FLI1. It targets an epitope within 91 amino acids from the C-terminal region.

Purified mouse monoclonal antibody IgG2b in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

1.0 mg/mL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommended storage: +2°C to +8°C.

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Friend leukemia integration 1 transcription factor (UniProt: Q01543; also known as Proto-oncogene Fli-1, Transcription factor ERGB) is encoded by the FLI1 gene (Gene ID: 2313) in human. FLI1 transcription factor is a member of the ETS family of transcription factors and plays critical roles in diverse biological processes, including cell proliferation, differentiation, apoptosis, and angiogenesis. FLI1 contains an ETS DNA-binding domain, which enables sequence-specific binding to target genes, and a sterile alpha motif (SAM) domain associated with protein-protein interactions. The protein regulates transcription mediated by RNA polymerase II. It is essential for normal hematopoiesis and vascular morphogenesis but is also implicated in oncogenesis, autoimmune diseases, and inflammatory conditions. RNA-binding protein EWS (EWSR1) is a member of the TET family, a highly conserved group of multifunctional, RNA-binding proteins that play critical roles in transcription regulation, RNA processing, and cellular signaling. Chromosomal translocations (most commonly the translocation t(11;22)(q24;q12), involving the Ewing sarcoma breakpoint region 1 gene (EWSR1) and FLI1 (EWSR1-FLI1 fusion gene) are a hallmark of Ewing sarcoma, driving tumorigenesis by aberrant regulation of genes associated with cell growth and survival. In the EWS-FLI1 fusion protein the RNA binding domains from the C terminus of EWS are replaced by the ETS DNA-binding domain of FLI1. Inhibitors of the EWSR1-FLI1 fusion protein in Ewing sarcoma are under investigation for their ability to mitigate tumor growth. (Ref.: Gong, H., et al., (2023). Cancers. 15(16), 4035; Erkizan H. V., (2010), Clin Cancer Res. 16 (16), 4077 4083)

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.